Behind the mechanism of action of brimonidine tartrate ophthalmic solution

News
Video

At the Tear Film and Ocular Surface meeting in Venice, Dr. Melissa Toyos shares findings on the mechanism of action of brimonidine tartrate.

At the Tear Film and Ocular Surface: Basic Science and Clinical Relevance meeting in Venice, Italy, Melissa Toyos, MD, presented her insights on ocular vascular constrictors, specifically focusing on brimonidine tartrate ophthalmic solution (Lumify; Bausch + Lomb). This presentation sheds light on the safety and efficacy of this innovative product, offering eye care providers essential information for patient care.

Toyos emphasized the widespread availability of over-the-counter vasoconstrictors, noting that while they provide quick relief from redness, their safety varies significantly. The key takeaway from her research, which involved a comprehensive analysis of 50 million units over four years, was the specific mechanism of action of Lumify. Unlike traditional redness relievers that act on alpha one adrenergic receptors—which constrict arteries and can compromise ocular nutrition—brimonidine selectively targets alpha two receptors. This distinction is crucial, as it minimizes potential side effects and reduces the risk of rebound redness, a common problem with conventional products.

One of the standout findings from Toyos’s study is that the occurrence of rebound redness with Lumify was extremely low, with only nine reported cases among the large sample size. This significantly lowers the risk of dependence that can occur with other redness relievers, which often lead to a cycle of overuse and increasing dissatisfaction. The study reported an almost negligible rate of ineffectiveness, underscoring Lumify’s safety profile.

Toyos also addressed the impact of brimonidine on the ocular surface. While the study primarily focused on self-reported adverse events, she noted the favorable vehicle composition of Lumify, which includes glycerin, making it comfortable for patients. The small active ingredient concentration further enhances its tolerability, setting it apart from other options.

In summary, Toyos encouraged eye care providers to embrace Lumify as a scientifically-backed option for managing ocular redness. She praised Bausch + Lomb’s commitment to research and safety, reinforcing that eye care professionals can confidently recommend Lumify to their patients without the fear of dependency or adverse effects associated with traditional vasoconstrictors. This innovative approach offers a promising solution for patients seeking relief from redness while maintaining the health of their ocular surface.

Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Tracy Doll, OD, FAAO, details portions of the Tear Film and Ocular Surface Society Lifestyle Report, which discussed certain risk factors that we may have for development of ocular surface dryness or dry eye.
Dr. Lisa Hornick goes over cosmetic habits and digital eye strain factors in OSD
Dr. Justin Schweitzer at AAOpt
Dr Pedram Hamrah
Ben Casella, OD, FAAO, talks 2024 EyeCon's networking and education opportunities
Tracy Lynn Schroeder Swartz O.D., M.S., FAAO, overviews her talk on comanagement
© 2024 MJH Life Sciences

All rights reserved.